1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Energenesis Biomedical Co., Ltd.

Energenesis Biomedical Co., Ltd.

TTWSE:6657
33.60
TWD
0.00
(0.00%)
-3.39EPS
3.20BMarket Cap
Nov 17Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.36
0.25
0.16
0.1
0.12
0.12
0.12
0.11
0.1
0.1
0.09
0.09
Basic EPS, GAAP
-2.27
-1.5
-2.19
-2.33
-2.81
-2.17
-1.98
-3.95
-3.62
-3.03
-2.92
-3.39
Free Cash Flow per Basic Share
-11.23
-1.06
-1.58
-1.95
-2.31
-1.74
-1.75
-3.56
-3.14
-2.38
-2.54
-2.31
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.4
4.62
5.16
8.95
13.23
11.19
12.73
8.93
10.48
9.58
10.19
8.11
Tangible Book Value per Share
1.35
2.26
3.07
7.18
11.94
10.12
11.96
8.36
10.14
9.4
10.18
8.11
Basic Weighted Avg Shares
7
24
32
45
53
60
61
67
72
76
88
88
Sales/Revenue/Turnover
2
6
5
5
6
7
7
7
7
8
8
8
Operating Margin (%)
-649.58
-596.53
-1,404.66
-2,340.84
-2,451.42
-1,886.54
-1,630.26
-3,695.47
-3,657.96
-3,292.93
-3,587.11
-4,108.6
Depreciation Expense
1
13
15
16
18
20
23
24
24
23
23
17
Net Income, GAAP
-15
-35
-71
-105
-150
-129
-120
-266
-260
-231
-258
-299
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-628.82
-587.01
-1,358.98
-2,251.76
-2,395.98
-1,828.54
-1,605.5
-3,613.98
-3,637.64
-2,982.06
-3,367.24
-3,908.52
Working Capital
44
84
117
330
636
532
713
479
698
652
821
639
LT Debt
35
35
33
35
9
10
6
4
3
5
9
7
Total Equity
69
228
255
452
786
673
852
603
804
739
896
713
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-23.65
-29.19
-29.59
-24.18
-17.74
-15.77
-36.52
-37.02
-29.95
-31.6
-34.15

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
9
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
88
88
88
Market Capitalization
3,783
3,587
3,200

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
864
802
704
Cash, Cash Equivalents & STI
838
776
677
Accounts Receivable, Net
1
1
1
Inventories
1
1
1
Total Current Liabilities
43
27
64
Payables & Accruals
- -
- -
- -
ST Debt
6
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
42.16%
8.8%
21.23%
Free Cash Flow
26.21%
25.31%
23.84%
Net Income, GAAP
42.83%
22.48%
11.82%
Sales/Revenue/Turnover
18.7%
1.72%
-0.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
2
2
3
8
2025
1
2
2
3
8
2026
1
2
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.56
-0.64
-1.17
-0.65
-3.03
2025
-1.1
-0.54
-0.55
-0.74
-2.92
2026
-0.53
-1.58
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Han Min Chen
Full Time Employees
34
Sector
Health technology
Industry
Biotechnology
Address
No.21, Ln.583, Ruiguang Road Taipei TP Taiwan 11492
IPO Date
Jun 12, 2023
Website
energenesis-biomedical.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Energenesis Biomedical Co., Ltd. operates within the biotechnology sector in Taiwan, concentrating on the advancement of novel therapeutic solutions. The company's pipeline includes ENERGI-F703DFU, a gel undergoing Phase III clinical evaluation for diabetic foot ulcers. Additionally, ENERGI-F701, a topical treatment for alopecia, has successfully completed Phase II trials. Its investigational ENERGI-F705PD, an oral tablet aimed at Parkinson's disease, recently concluded Phase I with favorable results and is slated for Phase II submission in 2025, offering a potential disease-modifying approach. Another candidate, ENERGI-F703EB cream for Epidermolysis Bullosa, has secured Orphan Drug designations from both the U.S. FDA and the EMA and is preparing for Phase II studies. The firm is also developing ENERGI-F711 for burns, ENERGI-F702 for various metabolic conditions, ENERGI-F704 targeting inflammatory bowel disease, ENERGI-F708 for asthma management, ENERGI-F707 addressing mitochondrial deficiencies, ENERGI-F706 to combat cachexia, ENERGI-F709 as a vaccine adjuvant, and ENERGI-F710 for regulating blood phosphate levels. Beyond its drug discovery efforts, Energenesis Biomedical supplies a range of scientific research products under the Visual Protein brand, encompassing items such as western blot reagents, cell culture supplements, protein isolation and quantification kits, various dyes, and buffer solutions. Established in 2012, the company maintains its headquarters in Taipei, Taiwan.